Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SLRN |
---|---|---|
09:32 ET | 5816 | 6.7002 |
09:33 ET | 300 | 6.7 |
09:35 ET | 3734 | 6.81 |
09:37 ET | 2513 | 6.82 |
09:39 ET | 400 | 6.81 |
09:42 ET | 1723 | 6.77 |
09:44 ET | 250 | 6.71 |
09:46 ET | 1098 | 6.74 |
09:48 ET | 1500 | 6.8 |
09:50 ET | 900 | 6.79 |
09:51 ET | 1900 | 6.79 |
09:53 ET | 1062 | 6.81 |
09:55 ET | 2067 | 6.8463 |
09:57 ET | 800 | 6.81 |
10:00 ET | 1129 | 6.795 |
10:02 ET | 3284 | 6.79 |
10:04 ET | 4500 | 6.775 |
10:06 ET | 300 | 6.78 |
10:08 ET | 2284 | 6.74 |
10:09 ET | 1180 | 6.74 |
10:11 ET | 2001 | 6.76 |
10:13 ET | 2500 | 6.78 |
10:15 ET | 900 | 6.77 |
10:18 ET | 11034 | 6.795 |
10:20 ET | 100 | 6.8 |
10:22 ET | 400 | 6.79 |
10:24 ET | 2599 | 6.81 |
10:26 ET | 1575 | 6.8 |
10:27 ET | 2013 | 6.78 |
10:29 ET | 1500 | 6.77 |
10:31 ET | 2368 | 6.78 |
10:33 ET | 1470 | 6.8 |
10:36 ET | 1647 | 6.81 |
10:38 ET | 1800 | 6.81 |
10:40 ET | 1664 | 6.808 |
10:42 ET | 2364 | 6.795 |
10:44 ET | 1079 | 6.81 |
10:45 ET | 849 | 6.845 |
10:47 ET | 300 | 6.84 |
10:49 ET | 1240 | 6.8796 |
10:51 ET | 823 | 6.87 |
10:54 ET | 200 | 6.87 |
10:56 ET | 2217 | 6.84 |
10:58 ET | 700 | 6.84 |
11:00 ET | 2203 | 6.86 |
11:02 ET | 1084 | 6.86 |
11:03 ET | 494 | 6.86 |
11:05 ET | 1016 | 6.86 |
11:07 ET | 963 | 6.87 |
11:09 ET | 721 | 6.855 |
11:12 ET | 783 | 6.839 |
11:14 ET | 4307 | 6.8003 |
11:16 ET | 835 | 6.79 |
11:18 ET | 1116 | 6.76 |
11:20 ET | 606 | 6.76 |
11:21 ET | 5354 | 6.735 |
11:23 ET | 1131 | 6.75 |
11:25 ET | 989 | 6.765 |
11:27 ET | 2158 | 6.78 |
11:30 ET | 2121 | 6.78 |
11:32 ET | 579 | 6.8 |
11:34 ET | 2212 | 6.795 |
11:36 ET | 1395 | 6.82 |
11:38 ET | 4585 | 6.85 |
11:39 ET | 1507 | 6.88 |
11:41 ET | 750 | 6.9 |
11:43 ET | 100 | 6.9 |
11:45 ET | 4899 | 6.885 |
11:48 ET | 700 | 6.87 |
11:50 ET | 200 | 6.88 |
11:52 ET | 300 | 6.86 |
11:54 ET | 1394 | 6.87 |
11:56 ET | 243 | 6.865 |
11:57 ET | 1756 | 6.869 |
11:59 ET | 888 | 6.87 |
12:01 ET | 2217 | 6.83 |
12:03 ET | 2571 | 6.87 |
12:06 ET | 300 | 6.87 |
12:08 ET | 800 | 6.87 |
12:10 ET | 1857 | 6.87 |
12:12 ET | 3642 | 6.86 |
12:15 ET | 1537 | 6.89 |
12:17 ET | 614 | 6.88 |
12:19 ET | 2381 | 6.88 |
12:21 ET | 629 | 6.89 |
12:24 ET | 300 | 6.89 |
12:26 ET | 2254 | 6.91 |
12:28 ET | 200 | 6.91 |
12:30 ET | 1291 | 6.905 |
12:32 ET | 200 | 6.9 |
12:33 ET | 800 | 6.89 |
12:35 ET | 2220 | 6.88 |
12:37 ET | 100 | 6.88 |
12:39 ET | 300 | 6.87 |
12:42 ET | 1260 | 6.885 |
12:44 ET | 940 | 6.885 |
12:46 ET | 600 | 6.89 |
12:48 ET | 5229 | 6.92 |
12:50 ET | 300 | 6.93 |
12:51 ET | 1200 | 6.92 |
12:53 ET | 437 | 6.93 |
12:55 ET | 1484 | 6.91 |
12:57 ET | 793 | 6.929 |
01:00 ET | 411 | 6.9203 |
01:02 ET | 2154 | 6.899 |
01:04 ET | 800 | 6.885 |
01:06 ET | 718 | 6.87 |
01:08 ET | 1104 | 6.88 |
01:09 ET | 713 | 6.89 |
01:11 ET | 232 | 6.89 |
01:13 ET | 2727 | 6.88 |
01:15 ET | 2457 | 6.92 |
01:18 ET | 744 | 6.96 |
01:20 ET | 300 | 6.96 |
01:22 ET | 100 | 6.965 |
01:24 ET | 700 | 6.95 |
01:26 ET | 1867 | 6.96 |
01:27 ET | 1021 | 6.955 |
01:29 ET | 1000 | 6.96 |
01:31 ET | 400 | 6.97 |
01:33 ET | 1337 | 6.96 |
01:36 ET | 200 | 6.97 |
01:40 ET | 1101 | 6.97 |
01:42 ET | 932 | 6.95 |
01:44 ET | 2897 | 6.98 |
01:45 ET | 1203 | 6.97 |
01:49 ET | 2400 | 6.95 |
01:51 ET | 200 | 6.96 |
01:54 ET | 200 | 6.95 |
01:56 ET | 1966 | 6.95 |
01:58 ET | 1227 | 6.94 |
02:00 ET | 1009 | 6.95 |
02:02 ET | 1200 | 6.95 |
02:03 ET | 2450 | 6.99 |
02:05 ET | 300 | 7 |
02:07 ET | 300 | 7.01 |
02:09 ET | 3782 | 7.01 |
02:12 ET | 400 | 7.02 |
02:14 ET | 1268 | 7.0276 |
02:16 ET | 100 | 7.02 |
02:18 ET | 2061 | 7.01 |
02:20 ET | 2462 | 7.015 |
02:21 ET | 1400 | 6.99 |
02:23 ET | 874 | 6.98 |
02:25 ET | 1688 | 6.99 |
02:27 ET | 200 | 6.99 |
02:30 ET | 266 | 7.0085 |
02:32 ET | 700 | 7 |
02:34 ET | 300 | 7.01 |
02:36 ET | 1759 | 7.01 |
02:38 ET | 200 | 7.005 |
02:39 ET | 4476 | 7 |
02:41 ET | 800 | 6.99 |
02:43 ET | 200 | 6.99 |
02:45 ET | 200 | 7 |
02:48 ET | 400 | 7 |
02:50 ET | 4886 | 6.98 |
02:52 ET | 854 | 6.97 |
02:54 ET | 1334 | 6.99 |
02:56 ET | 100 | 6.99 |
02:57 ET | 300 | 7 |
02:59 ET | 2718 | 6.971 |
03:01 ET | 200 | 6.96 |
03:03 ET | 1100 | 6.95 |
03:06 ET | 400 | 6.955 |
03:08 ET | 2727 | 6.965 |
03:10 ET | 2647 | 6.9125 |
03:12 ET | 200 | 6.93 |
03:15 ET | 100 | 6.93 |
03:17 ET | 700 | 6.92 |
03:19 ET | 200 | 6.94 |
03:21 ET | 3201 | 6.91 |
03:24 ET | 1552 | 6.93 |
03:26 ET | 2636 | 6.925 |
03:28 ET | 1500 | 6.91 |
03:30 ET | 300 | 6.915 |
03:32 ET | 1467 | 6.915 |
03:33 ET | 1708 | 6.92 |
03:35 ET | 5642 | 6.955 |
03:37 ET | 5479 | 6.93 |
03:39 ET | 500 | 6.93 |
03:42 ET | 5531 | 6.9 |
03:44 ET | 800 | 6.9 |
03:46 ET | 4472 | 6.9 |
03:48 ET | 5494 | 6.905 |
03:50 ET | 7029 | 6.88 |
03:51 ET | 3292 | 6.9 |
03:53 ET | 3713 | 6.895 |
03:55 ET | 10737 | 6.93 |
03:57 ET | 19549 | 6.92 |
04:00 ET | 17480 | 6.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACELYRIN Inc | 672.6M | 0.0x | --- |
Anavex Life Sciences Corp | 673.1M | -13.3x | --- |
89Bio Inc | 684.5M | -5.0x | --- |
Cabaletta Bio Inc | 688.2M | -9.2x | --- |
Centessa Pharmaceuticals PLC | 693.2M | -4.1x | --- |
Autolus Therapeutics PLC | 678.6M | -4.0x | --- |
ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The Company is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. It is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $672.6M |
---|---|
Revenue (TTM) | --- |
Shares Outstanding | 97.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $3.17 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.